Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Nifedipine XL Exclusivity Forfeited By Settling With Pfizer, Teva Says

Executive Summary

Mylan's generic nifedipine extended-release tablets should no longer be eligible for 180-day exclusivity because of the company's patent litigation settlement with Pfizer, Teva told FDA in a citizen petition.

You may also be interested in...



FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First

Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.

FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First

Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.

Mylan Nifedipine Settlement Revised Certification To Paragraph III, FDA Says

Mylan effectively amended its patent certification for its 30 mg extended-release nifedipine from paragraph IV to paragraph III by entering into an agreement with Pfizer to market "authorized generic" variants of Procardia XL and failing to launch its own approved version of the drug, FDA said Feb. 6.

Related Content

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel